Abivax S.A. (ABVX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Paris, France. Der aktuelle CEO ist Didier Blondel.
ABVX hat IPO-Datum 2023-10-20, 69 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $8.25B.
Abivax S.A. is a French biopharmaceutical company focused on discovering and developing drugs for inflammatory diseases, infectious diseases, and cancer. The company's lead candidate, ABX464, is in Phase IIb clinical trials for ulcerative colitis and Crohn's disease, with additional Phase IIa development for rheumatoid arthritis and completed Phase IIa trials for HIV viral remission. Abivax also develops ABX196, an immune-enhancing therapeutic in Phase 1/2 trials for hepatocellular carcinoma, alongside ongoing research programs targeting dengue fever, influenza, and respiratory syncytial virus. The company operates through partnerships with leading French research institutions including the French National Centre for Scientific Research, University of Montpellier, and Institut Curie. Founded in 2013 and headquartered in Paris, Abivax is advancing a diversified pipeline of novel immunotherapeutic candidates.
